News & analysis, rated.
Breaking AI developments, in-depth guides, real-world case studies, and analysis — each one rated so you know what matters.
Florida clinic cuts documentation time 85% with AI scribe platform
First Rehabilitation reduced therapist note time from 40 minutes to 5 minutes per patient while growing revenue 37% year-over-year.
Viridian's thyroid eye drug shows promise after Phase 3 miss
New chronic disease data for elegrobart looks competitive with Amgen's Tepezza after earlier trial disappointed investors.
CellCentric raises $220M for oral multiple myeloma drug
Series D round funds Phase 2/3 trials of inobrodib, targeting p300/CBP proteins in combination with existing treatments.
Avalo skin drug succeeds in trial; BioNTech cuts plants
Avalo reported positive study results for hidradenitis suppurativa treatment while BioNTech announced facility closures and staff reductions.
Novo's Wegovy pill hits $354M in Q1, beats estimates by 95%
The oral GLP-1 drug generated 2 million prescriptions since January launch, prompting Novo to revise full-year guidance upward as it competes with Lilly.
Bayer buys Perfuse for $2.45B to expand eye drug portfolio
The deal centers on a mid-stage glaucoma therapy and marks Bayer's first pharma acquisition in years, potentially its largest since AskBio in 2020.
CellCentric raises $220M Series D for myeloma pill
22-year-old biotech secures funding to target patients who have exhausted all other treatment options.
GSK signs $1B siRNA deal with China's SiranBio
British pharma giant doubles down on cardiometabolic treatments through partnership with Suzhou-based startup in crowded obesity space.
Avalo raises $375M after Phase 2 trial win in skin disorder
Biotech secured mid-stage success for experimental drug targeting inflammatory skin conditions as part of broader comeback strategy.
ParcelBio raises $13M for mRNA delivery tech
Two ex-Orbital scientists claim breakthrough in mRNA delivery, launch startup with seed funding to address technical bottlenecks.
Madrigal's MASH drug Rezdiffra beats Q1 estimates by $10M
Rezdiffra posted $311 million in first quarter sales, exceeding analyst projections in a competitive liver disease market.
OpenAI health policy blueprint serves company interests
Policy recommendations released with ChatGPT for Clinicians are reasonable but disproportionately benefit OpenAI, according to health policy experts.